Pfizer believes $43B Seagen deal positions it to fulfill most of 2030 revenue goal

Pfizer believes it can beat analysts’ expectations by extracting at least $10 billion in 2030 revenue from Seagen’s approved drugs and pipeline, justifying the pharma’s $43 billion purchase price to acquire the ADC developer.

Monday’s deal comes after weeks of rumors, and appears to culminate a process that stretches back to last summer, when Merck & Co. Inc. (NYSE:MRK) was reported to be in talks to acquire Seagen Inc. (NASDAQ:SGEN). The biotech went through a leadership change last year; CEO David Epstein replaced founding Chairman, President and CEO Clay Siegall, and steered Seagen through the sale process...